Table 4 Cytokines/chemokines in serum and CSF in the four study groups
Group 1 Definite LNB n = 49 Median (interquartile) | Group 2 Possible LNB pleocytosis n = 14 Median (interquartile) | Group 3 Possible LNB Ab+ n = 14 Median (interquartile) | Group 4 Non-LNB patients n = 88 Median (interquartile) | |
|---|---|---|---|---|
S-APRIL (ng/mL) | 3.1 (0.8–5.7) | 1.4 (0.3–1.8) | 2.0 (0.5–4.4) | 3.9 (0.0–5.8) |
S-BAFF (pg/mL) | 705 (471–857) | 586 (531–873) | 597 (496–763) | 730 (581–935) |
S-CXCL13 (pg/mL) | 67 (38–99) | 56 (39–84) | 41 (30–58) | 54 (34–81) |
S-IL-17A (pg/mL) | 4.0 (2.6–10) | 4.5 (2.9–9.2) | 5.6 (2.9–7.1) | 9.8 (2.6–24) |
S-CXCL1 (pg/mL) | 741 (549–861)*** | 695 (598–1055) | 599 (439–750)*** | 1113 (830–2425) |
S-CCL20 (pg(mL) | 6.1 (3.7–9.3)*** | 6.8 (5.3–13)*** | 5.2 (3.1–9.8) | 0.2 (0.2–8.2) |
CSF-APRIL (ng/mL) | 7.4 (4.7–17)*** | 7.0 (4.6–9.7)*** | 4.9 (3.9–6.1)*** | 0.0 (0.0–2.9) |
CSF-BAFF (pg/mL) | 113 (58–191)*** | 125 (81–203)*** | 0.0 (0.0–76) | 0.0 (0.0–25) |
CSF-CXCL13 (pg/mL) | 974 (738–2394)*** | 379 (57–770)*** | 3.4 (0.0–8.8)*** | 0.0 (0.0–0.0) |
CSF-IL-17A (pg/mL) | 0.6 (0.0–0.6)*** | 0.0 (0.0–0.2) | 0.0 (0.0–0.1) | 0.0 (0.0–0.0) |
CSF-CXCL1 (pg/mL) | 52 (16–117)*** | 16 (2.1–37) | 12 (4.4–21)* | 21 (16–26) |
CSF-CCL20 (pg/mL) | 2.5 (2.2–2.8)*** | 2.3 (1.9–2.6)*** | 2.2 (1.9–2.5)*** | 0.4 (0.4–0.4) |